Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study

Abstract We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP ± R (n = 17) or Burkitt lymphoma (BL) receiving CODOX-M/IVAC ± R (n = 15). The study was conducted in Beijing Ditan Hospital from January 2009 to Aug...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiang Xiao, Shuxu Du, Guorui Dai, Guiju Gao, Di Yang, Hongxin Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4e2768e99e29478a97e5d9f23fe47999
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e2768e99e29478a97e5d9f23fe47999
record_format	dspace
spelling	oai:doaj.org-article:4e2768e99e29478a97e5d9f23fe479992021-12-02T16:08:19ZEfficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study10.1038/s41598-017-02086-42045-2322https://doaj.org/article/4e2768e99e29478a97e5d9f23fe479992017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02086-4https://doaj.org/toc/2045-2322Abstract We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP ± R (n = 17) or Burkitt lymphoma (BL) receiving CODOX-M/IVAC ± R (n = 15). The study was conducted in Beijing Ditan Hospital from January 2009 to August 2015. The following grade 4 adverse effects were observed in BL and DLBCL patients, respectively: neutropenia (80% versus 47.1%), anaemia (46.7% versus 5.9%), thrombocytopenia (53.3% versus 11.8%), bacterial pneumonia (33.3% versus 5.9%), and sepsis (20% versus 5.9%) (p < 0.05). In the BL group, 10 (66.7%) patients died from treatment-related or tumour-related causes, 5 (33.3%) achieved complete response, 1 achieved partial response (6.7%), and 7 developed progressive disease. The 1-year overall survival and progression-free survival rates were 33.3%. Of the DLBCL patients, 3 (17.6%) died from treatment-related causes, 14 (82.4%) achieved complete response, and 3 had progressive disease. The 1-year overall survival and progression-free survival rates were 82.4%. The strongest risk factor for death was relapse between chemotherapy cycles (adjusted hazard ratio = 47.3; 95%CI, 4.2–528.6, p = 0.002). Initiating antiretroviral therapy before chemotherapy failed to improve overall survival. DLBCL patients demonstrated good responses and survival outcomes, while BL patients could not tolerate chemotherapy due to more severe toxicity, and showed poor responses and survival outcomes.Jiang XiaoShuxu DuGuorui DaiGuiju GaoDi YangHongxin ZhaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jiang Xiao Shuxu Du Guorui Dai Guiju Gao Di Yang Hongxin Zhao Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
description	Abstract We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP ± R (n = 17) or Burkitt lymphoma (BL) receiving CODOX-M/IVAC ± R (n = 15). The study was conducted in Beijing Ditan Hospital from January 2009 to August 2015. The following grade 4 adverse effects were observed in BL and DLBCL patients, respectively: neutropenia (80% versus 47.1%), anaemia (46.7% versus 5.9%), thrombocytopenia (53.3% versus 11.8%), bacterial pneumonia (33.3% versus 5.9%), and sepsis (20% versus 5.9%) (p < 0.05). In the BL group, 10 (66.7%) patients died from treatment-related or tumour-related causes, 5 (33.3%) achieved complete response, 1 achieved partial response (6.7%), and 7 developed progressive disease. The 1-year overall survival and progression-free survival rates were 33.3%. Of the DLBCL patients, 3 (17.6%) died from treatment-related causes, 14 (82.4%) achieved complete response, and 3 had progressive disease. The 1-year overall survival and progression-free survival rates were 82.4%. The strongest risk factor for death was relapse between chemotherapy cycles (adjusted hazard ratio = 47.3; 95%CI, 4.2–528.6, p = 0.002). Initiating antiretroviral therapy before chemotherapy failed to improve overall survival. DLBCL patients demonstrated good responses and survival outcomes, while BL patients could not tolerate chemotherapy due to more severe toxicity, and showed poor responses and survival outcomes.
format	article
author	Jiang Xiao Shuxu Du Guorui Dai Guiju Gao Di Yang Hongxin Zhao
author_facet	Jiang Xiao Shuxu Du Guorui Dai Guiju Gao Di Yang Hongxin Zhao
author_sort	Jiang Xiao
title	Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_short	Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_full	Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_fullStr	Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_full_unstemmed	Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_sort	efficacy and tolerability of chemotherapy in chinese patients with aids-related burkitt lymphoma and diffuse large b-cell lymphoma: an observational study
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/4e2768e99e29478a97e5d9f23fe47999
work_keys_str_mv	AT jiangxiao efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy AT shuxudu efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy AT guoruidai efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy AT guijugao efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy AT diyang efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy AT hongxinzhao efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy
_version_	1718384527543369728

Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study

Ejemplares similares